Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
BMC Cancer. 2023 Aug 10;23(1):740.
doi: 10.1186/s12885-023-11270-x.
1 Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, Heidelberg, 69126, Germany. Farastuk.Bozorgmehr@med.uni-heidelberg.de.
2 Translational Lung Research Center Heidelberg TLRCH, Member of the german Center for Lung Research DZL, Im Neuenheimer Feld 156, Heidelberg, 69120, Germany. Farastuk.Bozorgmehr@med.uni-heidelberg.de.
3 Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, Heidelberg, 69126, Germany.
4 Translational Lung Research Center Heidelberg TLRCH, Member of the german Center for Lung Research DZL, Im Neuenheimer Feld 156, Heidelberg, 69120, Germany.
5 Institute of Medical Biometry and Informatics, University Hospital of Heidelberg, Im Neuenheimer Feld 130.3, Heidelberg, 69120, Germany.
6 Translational Research Unit (STF), Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, Heidelberg, 69126, Germany.
7 Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital, Steinbacher Hohl 2-26, Frankfurt am main, 60488, Germany.
8 Department of Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, Göttingen, 37075, Germany.